WCLC 2023: Osimertinib Plus Chemotherapy Beneficial for Survival With EGFR-Mutated Advanced NSCLC
Findings seen for progression-free survival versus osimertinib alone, with study continuing to determine benefits for overall survival
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.